Literature DB >> 26289222

How to use vancomycin optimally in neonates: remaining questions.

Evelyne Jacqz-Aigrain1, Stephanie Leroux, Wei Zhao, John N van den Anker, Mike Sharland.   

Abstract

In neonates, vancomycin, a narrow-spectrum antibiotic, is the first choice of treatment of late-onset sepsis predominantly caused by Gram-positive bacteria (coagulase-negative staphylococci and enterococci). Although it has been used for >50 years, prescribing the right dose and dosing regimen remains a challenge in neonatal intensive care units for many reasons including high pharmacokinetic variability, increase in the minimal inhibition concentration against staphylococci, lack of consensus on dosing regimen and way of administration (continuous or intermittent), duration of treatment, use of therapeutic drug monitoring, limited data on short- and long-term toxicity, risk of mutant selection and errors of administration linked to concentrated formulations. This article highlights and discusses future research directions, with specific attention given to dosing optimization of vancomycin, including the advantages of modeling and simulation approaches.

Entities:  

Keywords:  continuous infusion; dosing optimization; formulation; modeling and simulation; neonates; nephrotoxicity; ototoxicity; pharmacokinetics; therapeutic drug monitoring; vancomycin

Mesh:

Substances:

Year:  2015        PMID: 26289222     DOI: 10.1586/17512433.2015.1060124

Source DB:  PubMed          Journal:  Expert Rev Clin Pharmacol        ISSN: 1751-2433            Impact factor:   5.045


  4 in total

1.  Clinical Utility and Safety of a Model-Based Patient-Tailored Dose of Vancomycin in Neonates.

Authors:  Stéphanie Leroux; Evelyne Jacqz-Aigrain; Valérie Biran; Emmanuel Lopez; Doriane Madeleneau; Camille Wallon; Elodie Zana-Taïeb; Anne-Laure Virlouvet; Stéphane Rioualen; Wei Zhao
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

2.  Factors impacting unbound vancomycin concentrations in neonates and young infants.

Authors:  Anne Smits; Steven Pauwels; Matthijs Oyaert; Nele Peersman; Isabel Spriet; Veroniek Saegeman; Karel Allegaert
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-05-16       Impact factor: 3.267

3.  Vancomycin therapeutic drug monitoring and population pharmacokinetic models in special patient subpopulations.

Authors:  Joaquim F Monteiro; Siomara R Hahn; Jorge Gonçalves; Paula Fresco
Journal:  Pharmacol Res Perspect       Date:  2018-07

4.  Population Pharmacokinetics of Vancomycin in Chinese ICU Neonates: Initial Dosage Recommendations.

Authors:  Zhi-Ling Li; Yi-Xi Liu; Zheng Jiao; Gang Qiu; Jian-Quan Huang; Yu-Bo Xiao; Shu-Jin Wu; Chen-Yu Wang; Wen-Juan Hu; Hua-Jun Sun
Journal:  Front Pharmacol       Date:  2018-06-26       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.